This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ETNB 89BIO (ETNB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About 89BIO Stock (NASDAQ:ETNB) Get 89BIO alerts:Sign Up Key Stats Today's Range$14.82▼$14.8750-Day Range$14.69▼$14.8752-Week Range$6.55▼$15.06Volume55.65 million shsAverage Volume3.57 million shsMarket Capitalization$2.20 billionP/E RatioN/ADividend YieldN/APrice Target$18.17Consensus RatingHold Company Overview 89bio, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for metabolic and endocrine disorders. The company’s lead investigational asset, BIO89-100 (pegozafermin), is a long-acting analog of fibroblast growth factor 21 (FGF21) designed to address underlying drivers of nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia and related metabolic diseases. By leveraging protein engineering and proprietary delivery technologies, 89bio aims to improve metabolic health through targeted modulation of lipid and glucose pathways. In addition to its NASH program, 89bio is exploring indications that include glycogen storage disease and other rare metabolic conditions with high unmet medical need. The company has advanced BIO89-100 into multiple clinical trials across North America and Europe, generating safety and efficacy data to support potential regulatory filings. Its research and development efforts are complemented by collaborations with academic centers and contract research organizations to accelerate patient enrollment and expand the understanding of FGF21 biology. Headquartered in Redwood City, California, 89bio was founded in 2018 and completed its initial public offering on the NASDAQ under the ticker ETNB in 2022. Under the leadership of Chief Executive Officer Arndt Zhang, the company is building a pipeline of endocrine therapies aimed at transforming the treatment landscape for patients with chronic metabolic diseases.AI Generated. May Contain Errors. Read More Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89BIO and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ETNB Stock News HeadlinesBiotech stocks are coming back. Here’s what will drive the sector higher.November 3, 2025 | msn.com89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNBOctober 6, 2025 | businesswire.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker. | Behind the Markets (Ad)Assessing 89bio (ETNB) Valuation Following a 60% Share Price RallyOctober 2, 2025 | finance.yahoo.com89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout DealSeptember 30, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB)September 23, 2025 | prnewswire.comRBC Capital Reaffirms Their Hold Rating on 89bio (ETNB)September 22, 2025 | theglobeandmail.comWolfe Research Downgrades 89bio (ETNB)September 19, 2025 | msn.comSee More Headlines ETNB Stock Analysis - Frequently Asked Questions How were 89BIO's earnings last quarter? 89BIO (NASDAQ:ETNB) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.22. When did 89BIO IPO? 89BIO (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager. What other stocks do shareholders of 89BIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that 89BIO investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Company Calendar Last Earnings8/07/2025Today5/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ETNB's financial health is in the Green zone, according to TradeSmith. ETNB has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ETNB CIK1785173 Webwww.89bio.com Phone415-432-9270FaxN/AEmployees40Year Founded2018Price Target and Rating Average Price Target for 89BIO$18.17 High Price Target$29.00 Low Price Target$11.00 Potential Upside/Downside+22.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($3.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$367.08 million Net MarginsN/A Pretax MarginN/A Return on Equity-94.48% Return on Assets-80.92% Debt Debt-to-Equity Ratio0.07 Current Ratio15.19 Quick Ratio15.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book4.44Miscellaneous Outstanding Shares148,310,000Free Float144,452,000Market Cap$2.20 billion OptionableOptionable Beta1.27 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:ETNB) was last updated on 5/18/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredThe filing was one thing. June 1 is another.The SpaceX filing got attention - but according to macroeconomic strategist Dr. Mark Skousen of The Oxford Clu...The Oxford Club | SponsoredGoldman’s bear market call is at odds with what earnings season is showing. Navellier says follow the data.Louis Navellier manages a $1.1 billion portfolio - including $358 million in AI stocks. He predicted the 2008 ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89BIO Please log in to your account or sign up in order to add this asset to your watchlist. Share 89BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ETNB Stock Alerts